A portfolio acquisition can look simple from the outside. A company adds products, gains access to new markets, and expands its ophthalmology business.
However, each acquired product brings its own supply network, technical files, manufacturing history, material sources, analytical methods, packaging components, regulatory commitments, and patient expectations. In glaucoma, those expectations are especially high. Patients often use eye drops every day for years. A short supply interruption, a packaging issue, or a shift in product quality can affect adherence and, in turn, disease control.
Catch glimpses of Yan Kugel‘s experience at CPHI Milan 2026 as he visited the NTC Pharma booth to have a discussion with Andrea Boccardi, the Head of Business Franchise, about their recent acquisition that added established glaucoma treatments to a portfolio that already includes products for dry eye, inflammation, and eye infections.
Why Chronic Glaucoma Therapy Raises the Stakes
Glaucoma is often called the “silent thief of sight” because vision loss may develop without obvious early symptoms. Once damage occurs, it cannot be reversed. For many patients, treatment means a daily routine of eye drops that continues for years.
That makes product consistency a patient-care issue.
A patient who has used the same therapy for months may notice even small changes. A bottle may feel different. The drop size may change. The treatment may sting more than before. The label may be unfamiliar. Any of these factors can affect confidence and adherence.
From a quality standpoint, ophthalmic products demand close control because they go directly into the eye. Key product attributes often include:
- Sterility and microbial control
- Particulate matter control
- pH and osmolality
- Assay and impurity profile
- Drop size and dose delivery
- Container-closure integrity
- Extractables and leachables
- Shelf-life stability
- In-use stability after opening
For a chronic glaucoma treatment, these attributes must remain within specification not only at release, but through distribution, storage, and repeated patient use.
This is why an acquisition is never just a commercial event. It is a quality and manufacturing transition that must protect a therapy patients depend on every day.
The Two-Part Growth Model Behind NTC’s Strategy
NTC’s glaucoma expansion appears to rest on two connected goals.
The first is portfolio growth. Adding glaucoma products can strengthen NTC’s position in a therapeutic area where the need for long-term treatment is clear and growing. Aging populations and improved diagnosis are likely to keep glaucoma management high on the agenda for health systems.
The second goal is technical differentiation. In ophthalmology, product value often comes from how a medicine is formulated, packed, manufactured, and experienced by the patient. A treatment may use a familiar active ingredient, yet still offer a different patient experience through a preservative-free format, a more practical delivery system, or better tolerability.
For manufacturing and quality leaders, the link between these two goals is direct. Portfolio growth can only deliver lasting value when each product can be made consistently, released with confidence, and supplied without disruption.
A new product line may bring revenue potential. It can also bring legacy deviations, aging equipment, limited supplier options, incomplete development data, or post-approval commitments that need close attention.
The work begins long before the first post-acquisition batch is released.
Quality Due Diligence Must Go Beyond the Dossier
Regulatory files are essential during an acquisition. They do not tell the full story.
A dossier describes the approved product. Quality due diligence must determine whether the real manufacturing operation consistently delivers that approved product.
This means looking closely at product history. Teams need to review deviations, out-of-specification investigations, complaints, recalls, inspection findings, stability trends, and batch-release performance. They also need to understand the practical details behind those records.
For example, a product may meet its release specification, yet show a recurring trend toward a stability limit. A site may have an approved alternate supplier, yet changing suppliers could require difficult comparability work. A filling line may have a strong past record, while also approaching capacity limits that could affect supply during demand growth.
The following questions often matter most:
Is the product technically well understood?
Quality teams should assess critical quality attributes and the manufacturing parameters that affect them. This includes formulation controls, sterilization approach, filtration conditions, filling parameters, and packaging performance.
For ophthalmic solutions, a small process shift can have a large effect. Filter blockage, hold-time variation, mixing behavior, or filling accuracy can affect quality and yield. A strong development package helps teams understand where the product is most sensitive.
Are analytical methods reliable and transferable?
Methods must be fit for their purpose, stable over time, and practical for the receiving site or contract laboratory. This includes assay, related substances, preservative content where relevant, sterility, endotoxin, particulate matter, and container-closure testing.
Method transfer is often treated as an administrative task. It is not. It is a performance exercise. The receiving laboratory must show that it can generate reliable results with its own analysts, instruments, reagents, and systems.
Does the supply base have enough resilience?
A product can have an approved manufacturer and still face a fragile supply chain. A single-source active ingredient, a specialized polymer, a unique bottle, or a limited sterile-filter supplier can become a supply risk.
Quality professionals should map not only direct suppliers but also key upstream sources. The point is to identify where one disruption could stop production.
Can the product meet future demand?
Capacity planning must include more than filling-line time. It must account for component lead times, aseptic processing windows, quality-control testing capacity, stability storage, serialization needs, release-cycle duration, and shipping requirements.
A supply plan that works at current volumes may fail when a newly acquired portfolio grows.
Preservative-Free Products Add a Different Layer of Manufacturing Challenge
Preservative-free ophthalmic products are a key area of interest in chronic eye care. Preservatives can help control microbial growth in multi-dose containers. Yet repeated exposure may contribute to ocular surface irritation in some patients, especially those who use drops over long periods or take several eye medicines.
For patients with glaucoma, tolerability can influence persistence with therapy. A treatment that causes less discomfort may support regular use.
That patient benefit comes with manufacturing trade-offs.
Preservative-free products cannot rely on a preservative system as a backstop after the container is opened. The full manufacturing and packaging system must provide stronger protection against microbial contamination.
Depending on the product format, this may involve unit-dose containers, multi-dose systems with microbial barriers, one-way valves, filtration features, or other specialized designs.
Each format creates its own quality requirements.
Aseptic control becomes even more central
Preservative-free ophthalmic products commonly require stringent aseptic processing. Manufacturers need well-designed cleanrooms, validated environmental monitoring, qualified operators, reliable sterilization processes, and disciplined intervention controls.
Media fills are a major part of this assurance. They should reflect the actual manufacturing process, including challenging interventions and realistic operating conditions. A simple media fill that does not represent routine risks gives little comfort.
Packaging is part of the product
For a preservative-free eye drop, the bottle and closure system are not merely a marketing choice. They are part of the microbial-control strategy.
The system must protect the formulation throughout shelf life and during patient use. It must dispense a consistent drop. It must resist leakage. It must withstand transport. It must not release harmful substances into the product. It also needs to work for patients who may have reduced dexterity or impaired vision.
This makes packaging qualification a cross-functional effort. Quality, engineering, regulatory, operations, and human-factors teams all have a role.
In-use studies matter
Traditional stability studies show how a sealed product performs over time. In-use studies address a different question. What happens once the patient opens the bottle and uses it repeatedly?
For ophthalmic products, this can include evaluating microbial performance, drop delivery, dose uniformity, container function, and physical appearance over the labeled period of use.
A product may be stable in a sealed container and still face challenges after first opening. The quality strategy must cover both conditions.
Securing Supply Without Losing Control
Supply continuity is a major concern in ophthalmology. Drug shortages can force patients to switch products, alter routines, or miss treatment. For glaucoma, even brief interruptions can cause anxiety and reduce trust in therapy.
A strong supply plan needs more than inventory. It needs a clear understanding of each point where material, information, or product can fail to move.
For NTC, securing the supply chain for an acquired glaucoma portfolio likely requires close work across several areas.
Supplier qualification and oversight
Suppliers of active ingredients, excipients, bottles, closures, filters, and printed materials need risk-based qualification. This includes quality agreements, audit programs, change-notification requirements, and performance monitoring.
A supply issue may start with a minor component. A cap colorant change, bottle resin shortage, or print supplier error can delay release just as effectively as an active ingredient failure.
Change control across companies and sites
Acquisitions often create a new network of partners. The prior owner may use one contract manufacturer. The acquiring company may prefer another. Moving production can make strategic sense, but it needs a controlled transfer plan.
The plan should define product knowledge transfer, equipment assessment, engineering batches, process performance qualification, analytical method transfer, stability commitments, regulatory filings, and commercial launch timing.
The fastest transfer is not always the safest transfer. Quality teams need enough time to establish evidence that the receiving operation can make the same product to the same standard.
Data integrity and documentation
Legacy records deserve careful review. Batch data, environmental monitoring records, validation reports, laboratory data, and supplier files must be complete, traceable, and accessible.
A portfolio transfer can expose document gaps that were manageable in the old organization but become difficult during a new inspection or registration renewal. Early document mapping can prevent late surprises.
Distribution and cold-chain assessment
Many ophthalmic products ship at controlled room temperature, though specific storage needs vary by product. Distribution studies must show that the chosen routes protect the product from temperature extremes, shock, and other transit conditions.
Quality teams should assess the full route from site to patient. This includes warehouses, wholesalers, pharmacies, and potential returns. A product that leaves the factory in specification must arrive at the patient in the same condition.
Manufacturing Excellence Depends on Product Knowledge
In pharmaceutical manufacturing, repeatability is built on knowledge.
Teams need to understand what makes a batch succeed. They need to know which variables are flexible and which ones are tightly linked to product quality. This is especially relevant in sterile ophthalmic manufacturing, where formulation, filtration, filling, and packaging act as one connected process.
Consider an ophthalmic solution with a low-dose active ingredient. Small errors in weighing, mixing, or dilution can have a meaningful effect on strength. Consider a product filled into a complex multi-dose bottle. A slight change in torque, assembly alignment, or component dimensions may affect dose delivery or container integrity.
These are not theoretical risks. They are practical manufacturing realities.
A strong control strategy links development knowledge to commercial operations. It defines:
- The material attributes that need close control
- The process parameters that affect product quality
- The tests that confirm batch acceptability
- The monitoring needed to detect drift over time
- The actions required when trends move in the wrong direction
For an acquired product, this knowledge may sit across several places. It may be found in development reports, old validation packages, batch records, experienced operators, and supplier files. Bringing it together is one of the most useful early steps after acquisition.
Beyond Glaucoma, the Same Lessons Apply
The manufacturing lessons from glaucoma apply across ophthalmology and other chronic therapies.
Patients who use long-term medicines need consistent quality. They need dependable availability. They need packaging they can use correctly. They need confidence that each refill will perform as expected.
For NTC, the glaucoma portfolio can serve as a practical test of how well commercial growth and operational discipline work together. The company’s ability to manage sterile production, specialized packaging, supplier risk, and technical transfer will shape the value of the acquisition long after the announcement date.
Quality is not a final checkpoint before distribution. It is the system that connects product design, supplier performance, manufacturing behavior, testing, release, and patient use.
What Quality and Manufacturing Teams Should Watch Next
The most meaningful signs of success will not appear only in sales figures. Quality and manufacturing professionals should watch for evidence of controlled execution.
That includes stable supply, strong batch-release performance, successful site transfers, reliable preservative-free packaging, clean inspection outcomes, and low complaint rates related to usability or product performance.
For chronic glaucoma therapy, every bottle carries a simple promise. The medicine should be available when the patient needs it. It should perform the same way each time. It should support treatment without creating avoidable barriers.
That promise is built in the supply chain and protected on the manufacturing floor.
Qualistery provides life‑science professionals with concise, practical GxP and cGMP learning through expert‑led webinars and tailored training, helping teams make safer, more compliant decisions. We deliver these sessions in partnership with trusted solution providers, combining real‑world insights and actionable guidance with targeted outreach to the right decision‑makers.
